Table 2.
Effect of bestatin in HIV-1 proviral copies
| Bestatin (μg/ml) | Days post-infection |
|||
|---|---|---|---|---|
| 0 | 3 | 5 | 7 | |
| 0 | 0 | 2127±119 | 3450±147 | 4949±470 |
| 20 | 0 | 895±113 | 1914±55 | 2669±98 |
| 40 | 0 | 485±28 | 932±73 | 1778±99 |
| 120 | 0 | 6±2 | 27±5 | 493±9 |
HUT78 cells were incubated with bestatin prior to infection, inactivated and the number of proviral copies determined using a quantitative PCR assay as described by (Conway et al., 1995). The data are expressed as mean values±S.D. (n=6). Cell treatment with bestatin for 7 days incubation did not affect cell survival (91.2–94.2%), thymidine incorporation (25.10–26.11 dpm×10-3), and the percent of CD4+ HUT78 cells (88.0–97.3%), in comparison to untreated cells.